European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...
The prevalence rises with age, reaching 5% to 7% among patients older than 70 years.[1][1] The differential diagnosis of an adrenal mass includes adenomas (both functional and nonfunctional), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback